Suppr超能文献

相似文献

1
Biological features and biomarkers in hepatocellular carcinoma.
World J Hepatol. 2015 Aug 8;7(16):2020-8. doi: 10.4254/wjh.v7.i16.2020.
2
Genetic alterations in hepatocellular carcinoma: An update.
World J Gastroenterol. 2016 Nov 7;22(41):9069-9095. doi: 10.3748/wjg.v22.i41.9069.
3
Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies.
J Hepatol. 2012 Jan;56(1):267-75. doi: 10.1016/j.jhep.2011.07.007. Epub 2011 Jul 23.
4
Novel mouse models of hepatocarcinogenesis with stepwise accumulation of genetic alterations.
Dig Dis. 2013;31(5-6):454-8. doi: 10.1159/000355244. Epub 2013 Nov 21.
5
Construction of a Comprehensive Multiomics Map of Hepatocellular Carcinoma and Screening of Possible Driver Genes.
Front Genet. 2020 Jun 25;11:634. doi: 10.3389/fgene.2020.00634. eCollection 2020.
7
Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma.
Oncoscience. 2015 May 15;2(5):443-456. doi: 10.18632/oncoscience.163. eCollection 2015.

引用本文的文献

1
Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines.
Hepatol Int. 2021 Dec;15(6):1421-1430. doi: 10.1007/s12072-021-10263-x. Epub 2021 Nov 6.
4
Elevated expression of cellular SYNE1, MMP10, and GTPase1 and their regulatory role in hepatocellular carcinoma progression.
Protoplasma. 2020 Jan;257(1):157-167. doi: 10.1007/s00709-019-01423-w. Epub 2019 Aug 19.
5
Biomarkers imaging in the early detection of hepatocellular carcinoma and prognosis.
World J Clin Cases. 2019 Jun 26;7(12):1367-1382. doi: 10.12998/wjcc.v7.i12.1367.
6
Staging systems of hepatocellular carcinoma: A review.
Indian J Gastroenterol. 2018 Nov;37(6):481-491. doi: 10.1007/s12664-018-0915-0. Epub 2018 Dec 29.
7
Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells.
Med Sci Monit. 2018 Mar 20;24:1642-1653. doi: 10.12659/msm.906075.
9
Clinical significance of mitofusin-2 and its signaling pathways in hepatocellular carcinoma.
World J Surg Oncol. 2016 Jul 7;14(1):179. doi: 10.1186/s12957-016-0922-5.
10
Hepatocellular carcinoma: Where are we?
World J Exp Med. 2016 Feb 20;6(1):21-36. doi: 10.5493/wjem.v6.i1.21.

本文引用的文献

1
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
Invest New Drugs. 2015 Jun;33(3):729-39. doi: 10.1007/s10637-015-0237-3. Epub 2015 Apr 12.
2
Hepatitis C.
Lancet. 2015 Mar 21;385(9973):1124-35. doi: 10.1016/S0140-6736(14)62401-6. Epub 2015 Feb 14.
3
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
Blood. 2015 Jan 8;125(2):346-57. doi: 10.1182/blood-2014-06-581082. Epub 2014 Nov 13.
5
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
Nat Med. 2014 Oct;20(10):1138-46. doi: 10.1038/nm.3679. Epub 2014 Sep 14.
6
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
J Hepatol. 2014 Aug;61(2):318-24. doi: 10.1016/j.jhep.2014.03.030. Epub 2014 Apr 2.
7
Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Cancer Discov. 2014 Jun;4(6):730-43. doi: 10.1158/2159-8290.CD-13-0782. Epub 2014 Mar 31.
8
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.
Nat Genet. 2014 Mar;46(3):225-233. doi: 10.1038/ng.2891. Epub 2014 Feb 2.
9
Exploration of liver cancer genomes.
Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):340-9. doi: 10.1038/nrgastro.2014.6. Epub 2014 Jan 28.
10
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma.
N Engl J Med. 2013 Jun 13;368(24):2266-76. doi: 10.1056/NEJMoa1300297.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验